Status:
NOT_YET_RECRUITING
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease
Lead Sponsor:
Assiut University
Conditions:
Paroxysmal Atrial Fibrillation
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The aim of this study is to study synergistic effect of eplerenone as Selective aldosterone receptor antagonist with amiodarone compared with amiodarone only in reducing recurrence of atrial fibrillat...
Detailed Description
Atrial fibrillation is the most common sustained arrhythmia, with a rising prevalence that substantially increases the risk of stroke and heart failure (1,2), The rate of recurrences without antiarrhy...
Eligibility Criteria
Inclusion
- \- paroxysmal AF who reverted to sinus rhythm either medically or electrically without appropriate secondary cause of primary AF
- •AF attack should be documented with ECG
Exclusion
- 1-patients are currently on eplerenone or spironolactone 2-hyperkalemia 3-impaired renal function(if CrCl \<50ml/min or serum creatinine\>2 mg/dl) 4-patient on beta blocker and calcium channel blocker (non- dihydropyridine) 5-prosthetic valve 6-severe mitral stenosis 7-thyroid dysfunction 8-WPW 9-severe liver disease 10-persistent or permanent AF 11-pregnancy or breast feeding 12-LV EF\<50% 13-known hypersensitivity or drug reaction to amiodarone 14-acute coronary syndrome 15-refusal of consent
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 20 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06168994
Start Date
February 1 2024
End Date
May 20 2027
Last Update
December 13 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.